임상 한눈에 보기

• 2건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 1, Phase 2 · Phase 1
• Status: Terminated
• 주요 endpoint: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) · Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) · Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events Based on Maximum Severity Grades · Number of Participants With AEs Leading to Dose Delays · Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
• 등록 대상자(표본 합산): 약 40명
• 선택한 코호트 보고 ORR: 0%
• 핵심: This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab i…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.